
Cleveland Clinic Abu Dhabi performs first robotic lung transplant in the gulf region
Cleveland Clinic Abu Dhabi has performed more than 60 lung transplants since 2022.
Abu Dhabi, United Arab Emirates: Cleveland Clinic Abu Dhabi has made history by performing the Gulf region's first-ever robotic lung transplant making it one of the five centers in the world to have performed this surgery. With this landmark complex surgery, two patients have now successfully undergone robotic lung transplants, marking a major milestone in the region's advanced surgical and organ transplant capabilities.
Both patients had idiopathic pulmonary fibrosis (IPF) as well as secondary pulmonary hypertension, a progressive condition that gradually scars the lungs and makes breathing increasingly difficult. Dr. Usman Ahmad, Chair of Thoracic Surgery, performed the complex robotic procedures along with a multi-disciplinary team of experts, including Drs. Yusuf Bayrak, Andres Obeso, Binu Esaw, Arun Kumar, and pulmonary experts including Drs. Fadi Hamed, Said Isse and Miriam Mihalechkova.
These surgeries were quite complex due to pulmonary hypertension, a condition that puts extra strain on the heart and lungs. To support the patients during the operation, the medical team used Veno-Arterial ECMO, a technique that temporarily takes over the work of the heart and lungs while the damaged lungs are replaced.
These life-saving surgeries would not have been possible without the extraordinary generosity of organ donor families, whose selfless gifts make such transplants possible. The hospital also acknowledges the critical role played by healthcare professionals from donor hospitals, the National Program for Organ Donation and Transplantation – HAYAT, the Department of Health- Abu Dhabi, and the National Center at the Ministry of Health and Prevention (MOHAP). Their collective efforts form the foundation of the UAE's organ donation and transplantation ecosystem and are vital to every success in this field. Recognizing their contributions honors the spirit of collaboration, compassion, and national progress that makes these achievements possible.
Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said: 'At Cleveland Clinic Abu Dhabi, we're proud to be global pioneers in robotic surgery, advancing the field of robotic transplantation and bringing new hope to patients in need. Being one of only a handful of centers in the world capable of performing these procedures reflects the exceptional skill, talent, and world-class expertise we have at Cleveland Clinic Abu Dhabi. It also reinforces Abu Dhabi's position as a global hub for healthcare innovation.'
Robotic-assisted surgery is rarely used in lung transplantation due to its complexity, however the surgical team's proven proficiency in performing advanced robotic procedures made it a viable option in these cases. Their expertise enabled them to carry out the transplant through smaller incisions, enhancing surgical precision, reducing recovery time, and minimizing pain and complications, even in such high-risk cases. This minimally invasive procedure represents the next generation of thoracic surgery offering hope to patients who may be considered too frail for traditional open surgery.
Dr. Usman Ahmad, Division Chair, Thoracic Surgery at Cleveland Clinic Abu Dhabi, said: 'Performing a robotic-assisted lung transplant requires not just the surgical expertise, but more importantly a fully integrated ecosystem of advanced technology, expert anesthesia support, and meticulous perfusion management. In these cases, the robotic approach was chosen due to its minimally invasive nature, which can be particularly beneficial for patients with severe frailty. By using smaller incisions and offering enhanced visualization, the robotic platform allowed us to reduce trauma to the chest, minimize bleeding, and accelerate recovery. This was one of the most complex operations we've ever undertaken, a high-stakes, high-reward scenario and it stands as a profound achievement not only for Cleveland Clinic Abu Dhabi, but for the UAE in its evolution in complex surgical care.'
The success of these procedures was made possible by a seamlessly coordinated, multidisciplinary effort that extended well beyond the operating room. From pre-surgical planning to post-transplant care, teams across surgery, anesthesia, and critical care worked together to ensure the best possible outcomes.
Building on that, Dr. Fadi Hamed, Staff Physician, Critical Care, Integrated Hospital Care Institute, said: 'What sets Cleveland Clinic Abu Dhabi's Lung Transplant Program apart is our ability to offer timely, high-quality care in a region where such advanced procedures were once considered out of reach, with success rates matching international benchmarks. Our patients benefit from significantly shorter wait times, access to size-matched donor organs through our integrated transplant network, and minimal ischemic time, which directly improves outcomes. In addition, our dedicated lung transplant and critical care teams, many of whom have undergone specialized training, work in perfect synergy to ensure patients receive the most cutting-edge, personalized care available. This level of coordination and innovation has truly positioned us as a regional leader in lung transplantation.'
Further solidifying its leadership in regional transplant medicine, Cleveland Clinic Abu Dhabi has surpassed a significant milestone this year, completing over 60 lung transplants since the relaunch of the program in 2022, establishing itself as the most advanced and active center of its kind in the region.
These cases exemplify the program's potential and underscores Cleveland Clinic Abu Dhabi's emergence as a global referral hub for patients with end-stage lung disease, including complex conditions such as Chronic Obstructive Pulmonary Disease as well as Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, and Bronchiectasis.
To learn more about Cleveland Clinic Abu Dhabi's Lung Transplant Program, visit: https://www.clevelandclinicabudhabi.ae/en/institutes-and-specialties/heart-vascular-and-thoracic-institute/lung-transplant-program
About Cleveland Clinic Abu Dhabi
Cleveland Clinic Abu Dhabi is a multispecialty hospital located on Al Maryah Island in Abu Dhabi, UAE. As an extension of Cleveland Clinic in the U.S., it is uniquely designed to address the complex and critical care needs of the UAE and the broader region. The hospital is organized into specialized Institutes, including Heart, Vascular & Thoracic; Neurological; Cancer; Digestive Disease; Medical Subspecialties; Integrated Surgical Subspecialties; Integrated Hospital Care; and Diagnostic.
Celebrating its 10th anniversary in 2025, Cleveland Clinic Abu Dhabi is a 405-bed hospital, including 321 acute care beds, 84 critical care beds, four royal suites, and 26 operating rooms. Its state-of-the-art facilities provide patients in the region with direct access to world-class healthcare providers and Cleveland Clinic's renowned model of care. The hospital is also home to the Fatima bint Mubarak Center, a dedicated cancer center offering comprehensive diagnostics and advanced treatment across 24 clinical departments, covering a range of cancer subspecialties and programs. Committed to medical innovation, Cleveland Clinic Abu Dhabi integrates robotics across specialties, pioneers' endovascular therapy and hybrid procedures, and offers comprehensive programs in heart failure, heart transplantation, and limb salvage.
Licensed by the Department of Health – Abu Dhabi as a designated research and teaching facility, Cleveland Clinic Abu Dhabi drives medical innovation through clinical trials and advanced research to enhance patient care. It is the first hospital in the UAE accredited by both the Accreditation Council for Graduate Medical Education International (ACGMEI) and the Accreditation Council for Continuing Medical Education (ACCME), offering residency and fellowship programs, undergraduate health professional training, and Continuing Medical Education (CME).
M42 is a global, tech-enabled healthcare company based in Abu Dhabi, operating at the forefront of medical advancement.
Media contact
Farah Chaaban – Farah.Chaaban@edelman.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Khaleej Times
8 hours ago
- Khaleej Times
GS1 UAE celebrates 25 years of enabling trust, transparency, and innovation
GS1 has marked 25 years of its presence in the UAE – empowering businesses and government entities with globally trusted standards that drive transparency, efficiency, and safety across supply chains. The milestone celebration coincides closely with a historic moment in global commerce today: in June of 1974, the very first product was scanned using a GS1 barcode in a supermarket in Ohio, USA. What began as a simple scan of a pack of chewing gum sparked a revolution in how the world tracks, sells, and understands products. Today, GS1 UAE stands at the forefront of that same legacy — helping businesses in the UAE digitize, standardize, and future-proof their operations. Since its establishment in 2000 in the United Arab Emirates, GS1 UAE has played a pivotal role in the UAE's digital transformation journey. Its globally recognized barcoding, data and traceability standards have become the backbone of key sectors as diverse as retail, healthcare, logistics, manufacturing, and e-commerce. Over the years, GS1 UAE has established strategic collaborations with several key government bodies, including the Federal Tax Authority (FTA), where its standards have been instrumental in enabling excise tax compliance and the traceability of Digital Tax Stamps. GS1 UAE has also supported the Ministry of Health and Prevention (MoHAP) through initiatives like Tatmeen that ensure the authentication of medical products, helping safeguard public health and align with national pharmaceutical safety goals. In the healthcare sector, GS1 UAE has partnered with health authorities such as Dubai Health, Emirates Drug Establishment, and Emirates Health Services, as well as hospitals such as Cleveland Clinic Abu Dhabi, and manufacturer associations such as Mecomed and Pharmag to implement serialization and traceability systems that strengthen patient safety, combat counterfeiting for pharmaceuticals and facilitate unique identification for medical devices. GS1's barcoding solutions in the retail and e-commerce industries have improved inventory accuracy, pricing consistency, and consumer trust, in collaboration with the likes of Dubai Duty Free, Al Ghurair, Transmed, Huda Beauty, Jumbo Electronics, Barakat, and Al Douri, to name a few. 'As we mark this important milestone, we reflect not only on our impact in the private sector but also on the strong partnerships we've built with UAE government institutions to promote trust and transparency at scale,' said Rami Habbal, CEO of GS1 UAE. 'From healthcare safety and regulatory compliance to consumer transparency and sustainability, GS1 UAE remains committed to delivering globally trusted standards that help the UAE lead in innovation.' Looking to the future, GS1 UAE is aligned with the global transition to next-generation QR codes powered by GS1 that will unlock richer trusted data at the point of sale. These QR codes will empower consumers, support sustainability efforts, and enhance real-time supply chain insights.


The National
10 hours ago
- The National
Fujairah's new Dh843m Sheikh Khalifa Hospital to boost emirate's health sector
A new flagship Dh843 million hospital primed to transform patient care in Fujairah has been hailed as one of the country's most advanced healthcare projects. The 222-bed Sheikh Khalifa Hospital was inaugurated by Sheikh Hamad bin Mohammed Al Sharqi, Ruler of Fujairah, and Sheikh Mansour bin Zayed, Vice President, Deputy Prime Minister and Chairman of the Presidential Court, on Tuesday. The state-of-the-art facility was established as part of the UAE President's Initiatives, a nationwide strategy providing essential funding for vital infrastructure projects that serve the public. The hospital spans 89,000 square metres and has the scope to expand its existing capacity to more than 350 beds. The Fujairah Ruler and Sheikh Mansour, accompanied by several officials, were given a tour of the hospital's extensive facilities, including centres of excellence, operating theatres, intensive care units, laboratories and inpatient wards. It features three dedicated medical centres of excellence, specialising in burns treatment, rehabilitation and trauma treatment, all equipped with cutting-edge technology to enhance services to patients. Sheikh Hamad stressed the importance of the new hospital in bolstering the emirate's health sector and enhancing the care delivered to patients. Sheikh Mansour said the hospital was one of the most important projects completed under the President's Initiatives programme. He said the hospital is central to a broader push to improve healthcare infrastructure across the Emirates. The hospital has high-tech features, including advanced imaging systems such as CT scans, MRI, and tomography, in addition to modern laboratories and specialised equipment for its three centres of excellence. It also has a modern emergency and trauma department with 30 beds, expandable to 60, and 55 outpatient clinics catering to diverse healthcare needs. Its rehabilitation centre features the latest therapeutic equipment, including speech therapy and audiometry, a hydrotherapy pool, two hyperbaric oxygen therapy rooms and advanced prosthetic support. The burns unit is comprises 10 patient rooms, five intensive care beds dedicated to burns, and an operating theatre equipped for such cases. The hospital also includes four royal suites, eight VIP suites, 45 beds across medical and surgical wings, 15 general intensive care beds and 10 cardiac ICU beds. The hospital is managed by The Medical Office (TMO) under PureHealth Group, which oversees the Sheikh Khalifa hospital network in the Northern Emirates, under the umbrella of the President's Initiatives and in co-ordination with the Presidential Court. It operates 24 hours a day, seven days a week, for emergency and inpatient services. Outpatient clinics receive patients from 8am to 5pm, Monday to Friday.


Khaleej Times
11 hours ago
- Khaleej Times
UAE becomes first country to approve oral drug for immune thrombocytopenia
The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton's tyrosine kinase (BTK) inhibitor to be authorised in the country for the treatment of Immune Thrombocytopenia (ITP), a rare autoimmune disorder that affects approximately 2 to 5 individuals per 100,000 people worldwide. With this landmark approval, the UAE becomes the first country in the world to authorise this innovative medication, reflecting the nation's global leadership in accelerating access to advanced treatments and addressing critical medical needs. The approval of Rilzabrutinib in the UAE represents a major step forward, offering patients with ITP early access to a pioneering therapeutic solution that contributes to a faster treatment journey and a tangible improvement in quality of life. The decision aligns with the UAE's strategic commitment to ensuring the availability of high-efficacy, globally benchmarked treatment s in line with the highest international standards and protocols. Developed by global pharmaceutical and healthcare company Sanofi, Rilzabrutinib represents a breakthrough in restoring immune system balance by targeting the underlying cause of ITP. By increasing platelet counts, the treatment addresses both the symptoms and root causes of the condition. Clinical studies have demonstrated promising outcomes, with patients reporting substantial improvement in health indicators. Dr Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, stated, 'The UAE is committed to providing access to the world's latest therapeutic innovations and further promoting its position as a regional hub for pharmaceutical excellence. With Rilzabrutinib getting approved, we take another step further in achieving our strategy aimed at enhancing national pharmaceutical security, implementing advanced treatment protocols, and streamlining regulatory frameworks in collaboration with international partners.' Dr Al Kaabi emphasised that the milestone demonstrates the effectiveness of the UAE's proactive healthcare policies and flexible regulatory systems in fostering innovation and facilitating patient access to advanced medications. 'The Emirates Drug Establishment will spare no effort to accelerate regulatory procedures, and strengthen global partnerships,' she said. 'This further solidifies the UAE's role as a regional centre for pharmaceutical innovation.' She added, 'Granting approval for Rilzabrutinib reaffirms the Establishment's commitment to fast-tracking access to transformative therapies that create significant impact, particularly in the treatment of rare and chronic diseases. EDE will continue to adopt a proactive, innovation-driven approach, fuelled by international collaboration, to ensure that safe, effective therapeutic options are available across the country in accordance with the highest global standards. Our goal is to enhance the UAE's health system preparedness in an era of rapid scientific progress.' For her part, Preeti Futnani, MCO Lead and General Manager, Specialty Care for KSA & Gulf Countries at Sanofi, said, 'We are honoured to collaborate with the Emirates Drug Establishment to bring this groundbreaking treatment to patients in the UAE living with Immune Thrombocytopenia. The approval of Rilzabrutinib demonstrates our shared commitment to placing patients at the centre of our mission and delivering cutting-edge solutions that address some of the most pressing unmet medical needs.'